<span item_type="fundamental" item_id="c39c158b9d53040ff08998122e520edd" counter_id="ST/US/ENGNW" env="prod"></span><span item_type="announcement" item_id="596567242001876481" env="prod"></span><p>Revenue: As of FY2025, the actual value is USD 0.</p><p>EPS: As of FY2025, the actual value is USD -2.29.</p><p>EBIT: As of FY2025, the actual value is USD -123.17 M.</p><p></p><h3>Operating Expenses</h3><ul><li>Total operating expenses for the full year ended October 31, 2025, were $123.2 million, compared to $62.3 million for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li><li>Research and development expenses increased by $56.2 million, primarily due to increased manufacturing, personnel, and clinical costs related to the LEGEND trial and preparation for the planned Biologics License Application submission.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li><li>General and administrative expenses increased by $4.7 million, driven by personnel and facilities costs as the company scales its operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss attributable to common shareholders was approximately $117.3 million, or $2.29 per share, for the full year ended October 31, 2025, compared to approximately $55.1 million, or $1.46 per share, for 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>As of October 31, 2025, cash, cash equivalents, and marketable securities were $202.3 million.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li><li>An additional $140.1 million in net proceeds was raised during a public offering in November.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li><li>The company expects that its cash and cash equivalents, together with the net proceeds from the November financing, will fund operating expenses, debt obligations, and capital expenditures into the second half of 2028.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>enGene plans to file a Biologics License Application for LEGEND’s pivotal cohort in the second half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li><li>The company anticipates providing a data update on the LEGEND trial’s pivotal cohort in the second half of 2026 following discussions with the FDA and accumulation of sufficient 12-month complete response data points.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li><li>enGene’s cash position is expected to extend its runway into the second half of 2028, supporting its focus on scaling the organization in preparation for the planned BLA filing and potential approval in 2027.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1980845/000119312525328706/engn-ex99_1.htm"></span></li></ul>

ENGENE HOLDINGS INC C/WTS 31/10/2028 (TO PUR COM) CL A | 8-K: FY2025 Revenue: USD 0